Myriad Genetics down after gene patent ruling

Myriad Genetics Inc. (NASDAQ:MYGN) fell $1.20 to $23.70 on Tuesday after the U.S. District Court for the Southern District on New York ruled on Monday that the company's patents covering the breast cancer 1 early onset (BRCA1) and BRCA2 genes were invalid. The company said on Tuesday that it will appeal to the Court of Appeals for the Federal Circuit (See BioCentury Extra, Monday, March 29, 2010). ...